PYC Therapeutics Ltd
ASX:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Volkswagen AG
XETRA:VOW
|
DE |
PYC Therapeutics Ltd
Interest Expense
PYC Therapeutics Ltd
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Interest Expense
AU$57.6k
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Interest Expense
$22.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Interest Expense
$421m
|
CAGR 3-Years
12%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Interest Expense
AU$13.8m
|
CAGR 3-Years
295%
|
CAGR 5-Years
154%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's Interest Expense?
Interest Expense
57.6k
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's Interest Expense amounts to 57.6k AUD.
What is PYC Therapeutics Ltd's Interest Expense growth rate?
Interest Expense CAGR 5Y
8%
Over the last year, the Interest Expense growth was 41%. The average annual Interest Expense growth rates for PYC Therapeutics Ltd have been 14% over the past three years , 8% over the past five years .
